The RAC Beta Serine/Threonine Protein Kinase pipeline drugs market research report outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the RAC Beta Serine/Threonine Protein Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Hematological Disorders, Non Malignant Disorders, and Undisclosed which include the indications Solid Tumor, Endometrial Cancer, Sickle Cell Disease, Proteus Syndrome, and Unspecified Rare Disease. It also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The RAC Beta Serine/Threonine Protein Kinase pipeline targets constitutes close to nine molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, and Preclinical stages are 1, 1, 3, and 2 respectively. Similarly, the universities portfolio in Phase I, and Preclinical comprises 1, and 1 molecule.
RAC Beta Serine/Threonine Protein Kinase overview
RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2.
For a complete picture of RAC Beta Serine/Threonine Protein Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
